Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles A Peloquin

Showing results (1-10 of 234) with videos related to

Pageof 24
Sort By:
Drugs|October 17, 2002
Therapeutic drug monitoring in the treatment of tuberculosisCharles A Peloquin
Antimicrobial Agents and Chemotherapy|February 17, 2012
Pharmacokinetic mismatch of tuberculosis drugsCharles A Peloquin
Drugs|May 22, 2014
Therapeutic drug monitoring in the treatment of tuberculosis: an updateAbdullah Alsultan, Charles A Peloquin
Expert Opinion on Pharmacotherapy|February 16, 2012
Antituberculosis therapy for 2012 and beyondMichael Lauzardo, Charles A Peloquin
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 4, 2017
Pharmacokinetics and pharmacodynamics of isoniazid in patients with intermediate resistanceAbdullah Alsultan, Charles A Peloquin
Expert Opinion on Pharmacotherapy|July 27, 2016
Tuberculosis therapy for 2016 and beyondMichael Lauzardo, Charles A Peloquin
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|May 6, 2024
Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosisNicole F Maranchick, Charles A Peloquin
Intensive Care Medicine|March 1, 2022
Another trial for the TARGET trialMohammad H Alshaer, Charles A Peloquin
Antimicrobial Agents and Chemotherapy|December 23, 2017
Reply to Chang et al., "Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?"Charles A Peloquin, Russell R Kempker
Expert Review of Clinical Pharmacology|August 23, 2016
Rifapentine for the treatment of latent tuberculosisEric F Egelund, Charles A Peloquin
Pageof 24

Showing results (1-10 of 234) with videos related to

Sort By:
Pageof 24
Drugs|October 17, 2002
Therapeutic drug monitoring in the treatment of tuberculosisCharles A Peloquin
Antimicrobial Agents and Chemotherapy|February 17, 2012
Pharmacokinetic mismatch of tuberculosis drugsCharles A Peloquin
Drugs|May 22, 2014
Therapeutic drug monitoring in the treatment of tuberculosis: an updateAbdullah Alsultan, Charles A Peloquin
Expert Opinion on Pharmacotherapy|February 16, 2012
Antituberculosis therapy for 2012 and beyondMichael Lauzardo, Charles A Peloquin
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 4, 2017
Pharmacokinetics and pharmacodynamics of isoniazid in patients with intermediate resistanceAbdullah Alsultan, Charles A Peloquin
Expert Opinion on Pharmacotherapy|July 27, 2016
Tuberculosis therapy for 2016 and beyondMichael Lauzardo, Charles A Peloquin
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|May 6, 2024
Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosisNicole F Maranchick, Charles A Peloquin
Intensive Care Medicine|March 1, 2022
Another trial for the TARGET trialMohammad H Alshaer, Charles A Peloquin
Antimicrobial Agents and Chemotherapy|December 23, 2017
Reply to Chang et al., "Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?"Charles A Peloquin, Russell R Kempker
Expert Review of Clinical Pharmacology|August 23, 2016
Rifapentine for the treatment of latent tuberculosisEric F Egelund, Charles A Peloquin
Pageof 24